These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34285470)

  • 1. Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes.
    Zhang Y; Chen R; Jia Y; Chen M; Shuai Z
    Drug Des Devel Ther; 2021; 15():3027-3040. PubMed ID: 34285470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K/Akt pathway in a GLP-1 receptor-dependent manner.
    Liu J; Yang K; Xiao W; Le Y; Lang S; Zhang J; Wei R; Yang J; Hong T
    Peptides; 2018 Aug; 106():83-90. PubMed ID: 30003931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvianolic acid a inhibits platelet activation and aggregation in patients with type 2 diabetes mellitus.
    Zhou AM; Xiang YJ; Liu EQ; Cai CH; Wu YH; Yang LB; Zeng CL
    BMC Cardiovasc Disord; 2020 Jan; 20(1):15. PubMed ID: 31931718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis.
    Cameron-Vendrig A; Reheman A; Siraj MA; Xu XR; Wang Y; Lei X; Afroze T; Shikatani E; El-Mounayri O; Noyan H; Weissleder R; Ni H; Husain M
    Diabetes; 2016 Jun; 65(6):1714-23. PubMed ID: 26936963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study.
    Li B; Hu Y; Wang G; Liu L
    BMC Pharmacol Toxicol; 2020 Jun; 21(1):44. PubMed ID: 32539783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
    Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
    Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation Research on Blood Glucose Fluctuation in Type 2 Diabetes Mellitus Patients and Vas- cular Endothelial Injury/Platelet Activation/PKCβ1 Expression].
    Wang JS; Huang Y; Chen KJ; Sun MY; Chen SL; Yin HJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Oct; 36(10):1184-1190. PubMed ID: 30641004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Patel D
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels.
    Parker WAE; Schulte C; Barwari T; Phoenix F; Pearson SM; Mayr M; Grant PJ; Storey RF; Ajjan RA
    Cardiovasc Diabetol; 2020 Jan; 19(1):3. PubMed ID: 31910903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.
    Zhang J; Xian TZ; Wu MX; Li C; Pan Q; Guo LX
    Cardiovasc Diabetol; 2020 Apr; 19(1):48. PubMed ID: 32334592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.
    Hu Y; Liu J; Zhang H; Xu Y; Hong T; Wang G
    Diabetes Metab; 2016 Nov; 42(5):358-363. PubMed ID: 27178737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed inhibition of agonist-induced granulocyte-platelet aggregation after low-dose sevoflurane inhalation in humans.
    Wacker J; Lucchinetti E; Jamnicki M; Aguirre J; Härter L; Keel M; Zaugg M
    Anesth Analg; 2008 Jun; 106(6):1749-58. PubMed ID: 18499605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet function alterations and their relation to P-selectin (CD62P) expression in children with iron deficiency anemia.
    Yıldırım ZK; Orhan MF; Büyükavcı M
    Blood Coagul Fibrinolysis; 2011 Mar; 22(2):98-101. PubMed ID: 21245745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Exenatide Use on Cognitive and Affective Functioning in Obese Patients With Type 2 Diabetes Mellitus: Exenatide Use Mediates Depressive Scores Through Increased Perceived Stress Levels.
    Eren-Yazicioglu CY; Kara B; Sancak S; Uysal SP; Yazici D; Okuroglu N; Whitton AE; Rutherford AV; Yapici-Eser H
    J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):428-435. PubMed ID: 34016830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
    Wang X; Zhang H; Zhang Q; Guan M; Sheng S; Mo W; Zou M; Li J; Bi J; Tang X; Zeng H; He J; Xu G; Li P; Xue Y
    Am J Nephrol; 2020; 51(10):806-814. PubMed ID: 32966971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of mild agonist stimulation on the platelet reactivity in patients with type 2 diabetes mellitus.
    Mahmoodian R; Salimian M; Hamidpour M; Khadem-Maboudi AA; Gharehbaghian A
    BMC Endocr Disord; 2019 Jun; 19(1):62. PubMed ID: 31200678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation.
    Barale C; Buracco S; Cavalot F; Frascaroli C; Guerrasio A; Russo I
    Thromb Haemost; 2017 Jun; 117(6):1115-1128. PubMed ID: 28405672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.